83-2271-39　［受注停止］KRIBIOLISA Semaglutide ELISA 1 x 96 wells　KBI5030

特徴

• Description：Immunoassay for Quantitative estimation of Semaglutide in
• human serum and plasma.
• Semaglutide （trade name Ozempic） is a pharmaceutical drug in development by a Danish company Novo
• Nordisk for the treatment of type 2 diabetes.
• It is marketed by the name Ozempic.
• As a glucagon-like peptide-1
• receptor agonist, it lowers the blood sugar level by increasing the production of insulin.
• It was discovered in
• 2012, by a team of researchers at Novo Nordisk as a longer-acting alternative to liraglutide.
• Clinical trials were
• started in 2015, and phase 3 was completed in 2016.
• FDA approval was applied in December 2016, and in
• October 2017 FDA Advisory Committee voted 16-0 in favor.
• It can be used as both injection-type or oral-type
• drug.
• About the kit：
• - Uses anti-idiotypic antibodies sourced from our vendor partner in the US, which ensures higher specificity, and low cross reactivity.
• - Recovery rates are between 85 - 115％
• - Ready to use with a standard protocol with break-apart pre-coated wells
• - Validated as per US FDA guidelines for Bioassays
• - Optimized for matrix effects to ensure higher sensitivity.
• - Shelf life： 1 year
• The Semaglutide ELISA is a competitive immunoassay for the determination of Semaglutide.
• The anti-GLP-1
• antibodies are coated on 96 well plate.
• A constant concentration of Biotinylated GLP-1 and varying
• concentration of unlabeled Semaglutide or sample compete for binding to anti-GLP-1 antibodies.
• Captured
• Biotinylated GLP-1 antibodies are subsequently bound by Streptavidin-HRP which produces a soluble colored
• product after addition of TMB substrate.
• The enzyme reaction is stopped by dispensing of stop solution into the
• wells.
• The optical density （OD） of the solution at 450 nm is inversely proportional to the amount of bound
• Semaglutide molecule present in standards or samples.